Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Oncocyte (Nasdaq: OCX), a diagnostics technology company, has scheduled its fourth quarter 2024 financial results announcement for March 24, 2025, after market close. The company will host a live Zoom webinar at 2:00 p.m. PT on the same day to discuss the results, followed by a Q&A session. Investors can access the webinar through registration, and a replay will be available on Oncocyte's investor relations website.
Oncocyte (Nasdaq: OCX), una società di tecnologia diagnostica, ha programmato l'annuncio dei risultati finanziari del quarto trimestre 2024 per il 24 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà un webinar Zoom in diretta alle 14:00 PT lo stesso giorno per discutere i risultati, seguito da una sessione di domande e risposte. Gli investitori possono accedere al webinar tramite registrazione e una registrazione sarà disponibile sul sito web delle relazioni con gli investitori di Oncocyte.
Oncocyte (Nasdaq: OCX), una empresa de tecnología de diagnóstico, ha programado el anuncio de sus resultados financieros del cuarto trimestre de 2024 para el 24 de marzo de 2025, después del cierre del mercado. La empresa llevará a cabo un webinar en Zoom en vivo a las 2:00 p.m. PT el mismo día para discutir los resultados, seguido de una sesión de preguntas y respuestas. Los inversores pueden acceder al webinar mediante registro, y una repetición estará disponible en el sitio web de relaciones con inversores de Oncocyte.
Oncocyte (Nasdaq: OCX), 진단 기술 회사가 2024년 4분기 재무 결과 발표를 2025년 3월 24일 시장 마감 후로 예정했습니다. 회사는 같은 날 오후 2시 PT에 결과를 논의하기 위한 Zoom 웨비나를 실시간으로 개최하며, 이후 Q&A 세션이 이어집니다. 투자자는 등록을 통해 웨비나에 접근할 수 있으며, Oncocyte의 투자자 관계 웹사이트에서 재생이 가능합니다.
Oncocyte (Nasdaq: OCX), une entreprise de technologie diagnostique, a programmé l'annonce de ses résultats financiers pour le quatrième trimestre 2024 pour le 24 mars 2025, après la fermeture du marché. L'entreprise organisera un webinaire Zoom en direct à 14h00 PT le même jour pour discuter des résultats, suivi d'une session de questions-réponses. Les investisseurs peuvent accéder au webinaire par inscription, et un enregistrement sera disponible sur le site web des relations investisseurs d'Oncocyte.
Oncocyte (Nasdaq: OCX), ein Unternehmen für Diagnosetechnologie, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal 2024 auf den 24. März 2025, nach Marktschluss, terminiert. Das Unternehmen wird am selben Tag um 14:00 Uhr PT ein Zoom-Webinar veranstalten, um die Ergebnisse zu besprechen, gefolgt von einer Fragerunde. Investoren können über eine Registrierung auf das Webinar zugreifen, und eine Aufzeichnung wird auf der Website der Investor Relations von Oncocyte verfügbar sein.
- None.
- None.
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar.
An archived replay will be available after the call concludes on Oncocyte’s investor relations website at https://investors.oncocyte.com.
About Oncocyte
Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When will Oncocyte (OCX) release its Q4 2024 earnings?
What time is Oncocyte's (OCX) Q4 2024 earnings call?
How can investors access Oncocyte's (OCX) Q4 2024 earnings call?
Where can I find the replay of Oncocyte's (OCX) Q4 2024 earnings call?
